Fecha de publicación: 24/05/2012 Fuente: WIPO "miel" The disclosure provides humanized, chimeric and murine antibodies that specificity bind to the human CC chemokine ligand 20 (CCL20). The disclosure further provides heavy chains and light chains of the antibodies, as well as isolated nucleic acids, recombinant vectors and host cells that comprise a sequence encoding a heavy chain and/or light chain of the antibodies. Further disclosed are methods of using the anti-CCL20 antibodies for treating disorders including inflammatory and autoimmune disorders as well as cancers.